By Daniella Parra
Araris Biotech AG joined a research agreement with Johnson & Johnson’s Janssen Biotech to advance the development of next-generation antibody-drug conjugates (ADCs), they said.
The partnership will leverage Araris’ proprietary AraLinQ technology, a one-step, enzymatic conjugation platform that creates uniform and potent ADCs with high efficiency as Araris is focused on transforming cancer treatment by replacing traditional chemotherapy with targeted ADCs, the company said.
“This is the third agreement established by Araris, after the successful collaboration with Taiho Pharmaceutical announced in November 2023, and with Chugai Pharmaceutical Co., Ltd most recently announced in January 2025,” Dr. Philipp Spycher, CSO of Araris, said. “This new agreement represents a further step to establish our AraLinQTM technology as a promising approach for ADC development.”
Contact:
